SynthesisFrontiers in immunology2020
Cell-Mediated Immune Responses to COVID-19 Infection.
Synthesis in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 70 citations in OpenAlex.
- Opposing Association of Lung Neutrophils and PD-L1Aging cell · 2026Article
- Seroepidemiological assessment of SARS-CoV-2 vaccine responsiveness and associated factors in the vaccinated community of the Casablanca-Settat Region, Morocco.Scientific reports · 2024Article
- Article
- Impaired antibody response to inactivated COVID-19 vaccines in hospitalized patients with type 2 diabetes.Human vaccines & immunotherapeutics · 2023Article
- Polymeric epitope-based vaccine induces protective immunity against group A Streptococcus.NPJ vaccines · 2023Article
- IL1β, IL-6, and TNF-α cytokines cooperate to modulate a complicated medical condition among COVID-19 patients: case-control study.Annals of medicine and surgery (2012) · 2023Article
- Natural killer cells in COVID-19: from infection, to vaccination and therapy.Future virology · 2023Review
- Review
- Identification of natural killer markers associated with fatal outcome in COVID-19 patients.Frontiers in cellular and infection microbiology · 2023Article
- Likelihood of COVID-19 reinfection in an urban community cohort in Massachusetts.Dialogues in health · 2022Article
- Omicron variant: Current insights and future directions.Microbiological research · 2022Review
- Need of booster vaccine doses to counteract the emergence of SARS-CoV-2 variants in the context of the Omicron variant and increasing COVID-19 cases: An update.Human vaccines & immunotherapeutics · 2022Article
- Detecting SARS-CoV-2 neutralizing immunity: highlighting the potential of split nanoluciferase technology.Journal of molecular cell biology · 2022Review
- Immunogenic and reactogenic efficacy of Covaxin and Covishield: a comparative review.Immunologic research · 2022Review
- Tea Polyphenols Prevent and Intervene in COVID-19 through Intestinal Microbiota.Foods (Basel, Switzerland) · 2022Review
- Actions and attitudes on the immunized patients against SARS-CoV-2.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2022Review
- Mutational Pattern, Impacts and Potential Preventive Strategies of Omicron SARS-CoV-2 Variant Infection.Infection and drug resistance · 2022Review
- Cellular heterogeneity in disease severity and clinical outcome: Granular understanding of immune response is key.Frontiers in immunology · 2022Review
- Article
- Comorbidity between lung cancer and COVID-19 pneumonia: role of immunoregulatory gene transcripts in highTherapeutic advances in medical oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An unprecedented outbreak of pneumonia caused by a novel coronavirus (CoV), subsequently termed COVID-19 by the World Health Organization, emerged in Wuhan City (China) in December 2019. Despite rigorous containment and quarantine efforts, the incidence of COVID-19 continues to expand, causing explosive outbreaks in more than 160 countries with waves of morbidity and fatality, leading to significant public health problems. In the past 20 years, two additional epidemics caused by CoVs have occurred: severe acute respiratory syndrome-CoV, which has caused a large-scale epidemic in China and 24 other countries; and respiratory syndrome-CoV of the Middle East in Saudi Arabia, which continues to cause sporadic cases. All of these viruses affect the lower respiratory tract and manifest as pneumonia in humans, but the novel SARS-Cov-2 appears to be more contagious and has spread more rapidly worldwide. This mini-review focuses on the cellular immune response to COVID-19 in human subjects, compared to other clinically relevant coronaviruses to evaluate its role in the control of infection and pathogenesis and accelerate the development of a preventive vaccine or immune therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.